Sign In
Buy MRK
$113.87
-1.62 (-1.40%)
At Close: Jun 18, 2026
5 Relatively Secure And Cheap Dividend Stocks To Invest In -- October 2024
09:00am, Saturday, 05'th Oct 2024
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering pr
Is It Time to Buy September's Worst-Performing Dow Jones Stocks?
05:25am, Saturday, 05'th Oct 2024
They may technically be blue chips, but that doesn't necessarily make them your best bets at their discounted prices.
Buy 2 October Dogs Of The Dow And Watch 5 More
02:38am, Saturday, 05'th Oct 2024
"The Dow® [adds a stock] if the company has an excellent reputation,
3 Bargain Stocks Positioned for Gains After Missing 2024's Rally
10:27am, Friday, 04'th Oct 2024
By most accounts, the stock market has had a very good 2024. The S&P 500 has provided a total return so far of 20.6%.
3 Top Pharma Stocks to Buy in October 2024
08:11am, Thursday, 03'rd Oct 2024
The pharmaceutical industry plays a crucial role in most of our everyday lives.
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
01:16pm, Tuesday, 01'st Oct 2024
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
06:45am, Tuesday, 01'st Oct 2024
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of CN201 from Curon Biopharmaceutical (Curon),
Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31
06:30am, Tuesday, 01'st Oct 2024
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31.
Is Merck Stock a Buy?
06:28am, Sunday, 29'th Sep 2024
Merck's Keytruda could face competition from a newer medicine. The company's crown jewel will also lose patent exclusivity in a few years.
Merck (MRK) Stock Sinks As Market Gains: Here's Why
06:56pm, Thursday, 26'th Sep 2024
In the latest trading session, Merck (MRK) closed at $113.09, marking a -1.43% move from the previous day.
MRK's Keytruda Combo Fails in Phase III Colorectal Cancer Study
01:20pm, Thursday, 26'th Sep 2024
The phase III KEYFORM-007 study, evaluating Merck's Keytruda plus favezelimab for treating metastatic colorectal cancer, fails to meet the primary endpoint.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data highlighting the long-term efficacy and safety of tulisokibart (MK
When Buffett Meets Bannister
10:30am, Wednesday, 25'th Sep 2024
Barry Bannister, Managing Director and Chief Equity Strategist at Stifel, put out an excellent research piece on future returns based on what industry folks call the “equity risk premium.” He says
Merck says trial of combination treatment for colon cancer failed to meet main goal
07:24am, Wednesday, 25'th Sep 2024
Merck & Co.'s said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal of overall survival (OS) as a treatment for a type of colon c
Merck's colorectal cancer therapy fails late-stage trial
06:59am, Wednesday, 25'th Sep 2024
Merck said on Wednesday its therapy did not meet the main goal of a late-stage trial evaluating it in patients with a type of colorectal cancer.
